Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
<p><strong>Objectives:</strong> Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor belonging to a distinct class of enzyme inhibitors. In a phase 2 trial in psoriatic arthritis (NCT03881059), deucravacitinib was significantly more efficacious...
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Journal article |
| Lingua: | English |
| Pubblicazione: |
Oxford University Press
2024
|
| _version_ | 1826317048193482752 |
|---|---|
| author | Kavanaugh, A Coates, LC Mease, PJ Nowak, M Hippeli, L Lehman, T Banerjee, S Merola, JF |
| author_facet | Kavanaugh, A Coates, LC Mease, PJ Nowak, M Hippeli, L Lehman, T Banerjee, S Merola, JF |
| author_sort | Kavanaugh, A |
| collection | OXFORD |
| description | <p><strong>Objectives:</strong> Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2
(TYK2) inhibitor belonging to a distinct class of enzyme inhibitors. In a phase 2 trial in psoriatic arthritis (NCT03881059), deucravacitinib was significantly more efficacious than placebo across multiple endpoints, including achieving minimal disease activity (MDA). This post hoc analysis further evaluated the achievement of individual components of the MDA criteria with deucravacitinib treatment and the time course of responses in the phase 2 trial.</p>
<br>
<p><strong>Methods:</strong> Patients (N = 203) were randomized 1:1:1 to once daily treatment with placebo, deucravacitinib 6 mg, or deucravacitinib 12 mg. The proportions of patients achieving MDA and each of the 7 individual MDA components through Week 16 were assessed.</p>
<br>
<p><strong>Results:</strong> At baseline, although some patients met criteria for individual MDA components, none of the patients met the composite MDA criterion, and all components were balanced overall across treatment arms. Treatment with deucravacitinib was associated with a numerically greater mean reduction from baseline in all MDA components vs placebo over 16 weeks of treatment. At Week 16, a greater percentage of patients treated with either dose of deucravacitinib vs placebo achieved the threshold criteria for meeting MDA in each of the components.</p>
<br>
<p><strong>Conclusions:</strong> More patients treated with deucravacitinib met each of the MDA components vs placebo, along with a higher rate of MDA response, after 16 weeks of treatment.</p> |
| first_indexed | 2024-12-09T03:12:46Z |
| format | Journal article |
| id | oxford-uuid:ef93c1fe-e9a1-4e1b-a4cc-a2ceb67ee573 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2025-02-19T04:33:59Z |
| publishDate | 2024 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:ef93c1fe-e9a1-4e1b-a4cc-a2ceb67ee5732025-01-14T08:31:26ZDeucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ef93c1fe-e9a1-4e1b-a4cc-a2ceb67ee573EnglishSymplectic ElementsOxford University Press2024Kavanaugh, ACoates, LCMease, PJNowak, MHippeli, LLehman, TBanerjee, SMerola, JF<p><strong>Objectives:</strong> Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor belonging to a distinct class of enzyme inhibitors. In a phase 2 trial in psoriatic arthritis (NCT03881059), deucravacitinib was significantly more efficacious than placebo across multiple endpoints, including achieving minimal disease activity (MDA). This post hoc analysis further evaluated the achievement of individual components of the MDA criteria with deucravacitinib treatment and the time course of responses in the phase 2 trial.</p> <br> <p><strong>Methods:</strong> Patients (N = 203) were randomized 1:1:1 to once daily treatment with placebo, deucravacitinib 6 mg, or deucravacitinib 12 mg. The proportions of patients achieving MDA and each of the 7 individual MDA components through Week 16 were assessed.</p> <br> <p><strong>Results:</strong> At baseline, although some patients met criteria for individual MDA components, none of the patients met the composite MDA criterion, and all components were balanced overall across treatment arms. Treatment with deucravacitinib was associated with a numerically greater mean reduction from baseline in all MDA components vs placebo over 16 weeks of treatment. At Week 16, a greater percentage of patients treated with either dose of deucravacitinib vs placebo achieved the threshold criteria for meeting MDA in each of the components.</p> <br> <p><strong>Conclusions:</strong> More patients treated with deucravacitinib met each of the MDA components vs placebo, along with a higher rate of MDA response, after 16 weeks of treatment.</p> |
| spellingShingle | Kavanaugh, A Coates, LC Mease, PJ Nowak, M Hippeli, L Lehman, T Banerjee, S Merola, JF Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial |
| title | Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial |
| title_full | Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial |
| title_fullStr | Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial |
| title_full_unstemmed | Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial |
| title_short | Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial |
| title_sort | deucravacitinib a selective tyk2 inhibitor in psoriatic arthritis achievement of minimal disease activity components in a phase 2 trial |
| work_keys_str_mv | AT kavanaugha deucravacitinibaselectivetyk2inhibitorinpsoriaticarthritisachievementofminimaldiseaseactivitycomponentsinaphase2trial AT coateslc deucravacitinibaselectivetyk2inhibitorinpsoriaticarthritisachievementofminimaldiseaseactivitycomponentsinaphase2trial AT measepj deucravacitinibaselectivetyk2inhibitorinpsoriaticarthritisachievementofminimaldiseaseactivitycomponentsinaphase2trial AT nowakm deucravacitinibaselectivetyk2inhibitorinpsoriaticarthritisachievementofminimaldiseaseactivitycomponentsinaphase2trial AT hippelil deucravacitinibaselectivetyk2inhibitorinpsoriaticarthritisachievementofminimaldiseaseactivitycomponentsinaphase2trial AT lehmant deucravacitinibaselectivetyk2inhibitorinpsoriaticarthritisachievementofminimaldiseaseactivitycomponentsinaphase2trial AT banerjees deucravacitinibaselectivetyk2inhibitorinpsoriaticarthritisachievementofminimaldiseaseactivitycomponentsinaphase2trial AT merolajf deucravacitinibaselectivetyk2inhibitorinpsoriaticarthritisachievementofminimaldiseaseactivitycomponentsinaphase2trial |